Gemzar (Ovarian Cancer) Analysis and Forecasts to 2020


#28292

34pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Gemzar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Gemzar including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Gemzar including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2004-2020 for Gemzar in the seven major markets

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Market Forecasts Report Guidance 8


3 Ovarian Cancer: Market Characterization 9
3.1 Ovarian Cancer Market 9
3.2 Ovarian Cancer Market Forecasts and CAGR 9
3.3 Drivers for Ovarian Cancer Market 10
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 12
3.3.4 Emergence of Targeted Drugs 12
3.3.5 Recurrence of Tumor 12
3.3.6 Low Initial Diagnosis Rate 12


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 13


5 Gemzar 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 16
5.4 Approval History of Gemzar 17
5.5 Factors Affecting Sales of Gemzar 17
5.5.1 Generic Erosion 17
5.5.2 High Efficacy 17
5.5.3 Average Toxicity 17
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of Competition 18
5.7 Sales Forecasts 18
5.7.1 Target Patient Pool of Gemzar 19
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 20
5.7.5 Sales Projections of Gemzar 21


6 Ovarian Cancer Market: Appendix 30
6.1 Market Definitions 30
6.2 List of Abberiviations 30
6.3 Research Methodology 30
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 32
6.3.6 Net Annual Dosing 33
6.3.7 Annual Cost of Therapy 33
6.3.8 Primary Research 33
6.3.9 Expert Panels 33
6.4 Contact Us 33
6.5 Disclaimer 34
6.6 Sources 34


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Table 3: Detailed TNM Classification 14
Table 4: Phase III Clinical Trial Results of Gemzar plus Carboplatin versus Carboplatin 17
Table 5: Drug Risk Benefit Score of Gemzar 18
Table 6: Annual Cost of Therapy of Gemzar, 2011 20
Table 7: Gemzar, Ovarian Cancer, Global, Sales Estimates ($m), 20042020 21
Table 8: Gemzar, Ovarian Cancer, The US, Sales Estimates ($m), 20062020 22
Table 9: Gemzar, Ovarian Cancer, The UK, Sales Estimates ($m), 20042020 23
Table 10: Gemzar, Ovarian Cancer, France, Sales Estimates ($m), 20042020 24
Table 11: Gemzar, Ovarian Cancer, Germany, Sales Estimates ($m), 20042020 25
Table 12: Gemzar, Ovarian Cancer, Italy, Sales Estimates ($m), 20042020 26
Table 13: Gemzar, Ovarian Cancer, Spain, Sales Estimates ($m), 20042020 27
Table 14: Gemzar, Ovarian Cancer, Japan, Sales Forecasts ($m), 20112020 28


Figure 1: Distribution by Incidence and Mortality, Most Frequently Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 9
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 10
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 11
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 11
Figure 6: Broad Classification of Ovarian Cancer 13
Figure 7: Classification of Ovarian Cancer 15
Figure 8: Drug Model Diagram of Gemzar 19
Figure 9: Gemzar, Ovarian Cancer, Global, Sales Estimates ($m), 2004-2020 21
Figure 10: Gemzar, Ovarian Cancer, The US, Sales Estimates ($m), 2006-2020 22
Figure 11: Gemzar, Ovarian Cancer, The UK, Sales Estimates ($m), 2004-2020 23
Figure 12: Gemzar, Ovarian Cancer, France, Sales Estimates ($m), 2004-2020 24
Figure 13: Gemzar, Ovarian Cancer, Germany, Sales Estimates ($m), 2004-2020 25
Figure 14: Gemzar, Ovarian Cancer, Italy, Sales Estimates ($m), 2004-2020 26
Figure 15: Gemzar, Ovarian Cancer, Spain, Sales Estimates ($m), 2004-2020 27
Figure 16: Gemzar, Ovarian Cancer, Japan, Sales Forecasts ($m), 2011-2020 28
Figure 17: Gemzar, Ovarian Cancer, Sales Distribution by Country (%), 2011 29
Figure 18: Drug Model Diagram 32
Figure 19: Patients Approved for the Drug 32